Omeros Corp
OMER3.520USD
-0.090-2.49%
交易中 （美东）报价延迟15分钟
204.38M总市值
亏损市盈率 TTM
关于 Omeros Corp 公司
Omeros Corporation 是一家生物制药公司。该公司专注于发现、开发和商业化小分子和蛋白质疗法，用于治疗免疫疾病（包括补体介导的疾病、癌症以及成瘾和强迫症）的大市场和孤儿适应症。其主要 MASP-2 抑制剂 narsoplimab 靶向补体的凝集素途径，是 FDA 正在等待批准的生物制剂许可申请的主题，用于治疗造血干细胞移植相关的血栓性微血管病。其长效 MASP-2 抑制剂 OMS1029 正处于 I 期多剂量递增临床试验中。其 MASP-3 抑制剂 OMS906 是补体替代途径的关键激活剂，正在阵发性睡眠性血红蛋白尿和补体 3 肾小球病的临床项目中取得进展。该公司的主要磷酸二酯酶 7 抑制剂 OMS527 目前正在进行治疗可卡因使用障碍的临床开发。
公司简介
公司代码OMER
公司名称Omeros Corp
上市日期Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
员工数量202
证券类型Ordinary Share
年结日Oct 08
公司地址201 Elliott Avenue West
城市SEATTLE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编98119
电话12066765000
网址https://www.omeros.com/
公司代码OMER
上市日期Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月17日 周四
更新时间: 7月17日 周四
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
16.95%
Investment Advisor
15.51%
Hedge Fund
3.93%
Individual Investor
3.84%
Research Firm
3.66%
Bank and Trust
0.89%
Insurance Company
0.13%
Pension Fund
0.10%
Other
55.00%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
251
30.23M
45.04%
-382.24K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
2023Q1
308
23.79M
37.88%
-4.75M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
4.02M
6.87%
+58.15K
+1.47%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
3.98M
6.79%
-30.05K
-0.75%
Mar 31, 2025
The Vanguard Group, Inc.
3.24M
5.53%
+95.60K
+3.04%
Mar 31, 2025
Demopulos (Gregory A. M.D.)
2.03M
3.46%
--
--
May 23, 2025
D. E. Shaw & Co., L.P.
1.94M
3.31%
+99.63K
+5.42%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
1.56M
2.66%
-24.56K
-1.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.37M
2.34%
+29.70K
+2.22%
Mar 31, 2025
State Street Global Advisors (US)
1.36M
2.31%
+144.57K
+11.93%
Mar 31, 2025
Corient Private Wealth LLC
720.42K
1.23%
-13.03K
-1.78%
Mar 31, 2025
Nomura Securities Co., Ltd.
679.02K
1.16%
-68.26K
-9.13%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.44%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Invesco Dynamic Buyback Achievers ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.44%
Vanguard US Momentum Factor ETF
占比0.12%
iShares Micro-Cap ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Invesco Dynamic Buyback Achievers ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
